Stroke remains a leading cause of morbidity and mortality worldwide, necessitating the development of rapid and reliable diagnostic tools for early detection and management. This manuscript presents an overview of innovative biosensors designed for the detection of key stroke biomarkers, including N-terminal pro B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), D-dimer, cardiac troponins, S100B protein, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), matrix metalloproteinases (MMPs), interleukins and fibrinogen. We discuss the principles of operation, sensitivity, specificity and the technological advancements that have enabled the development of these biosensors, including electrochemical, optical and microfluidic platforms. The integration of nanomaterials and advanced signal amplification techniques has significantly enhanced the performance of these biosensors, allowing for the detection of biomarkers at low concentrations in complex biological samples. Furthermore, we explore the clinical implications of these biosensors in the context of stroke diagnosis, prognosis and monitoring, highlighting their potential to facilitate timely therapeutic interventions. By providing a comprehensive discussion on the current state of biosensor technology for stroke biomarker detection, this manuscript aims to underscore the importance of these tools in improving patient outcomes and advancing stroke research. Future directions for biosensor development and the challenges that remain in translating these technologies into clinical practice are also addressed.
Koohkansaadi et al. (2025) studied this question.